Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
| Autor: | Yoshio Sumida, Masashi Yoneda, Hidenori Toyoda, Satoshi Yasuda, Toshifumi Tada, Hideki Hayashi, Yoichi Nishigaki, Yusuke Suzuki, Takafumi Naiki, Asahiro Morishita, Hiroshi Tobita, Shuichi Sato, Naoto Kawabe, Shinya Fukunishi, Tadashi Ikegami, Takaomi Kessoku, Yuji Ogawa, Yasushi Honda, Takashi Nakahara, Kensuke Munekage, Tsunehiro Ochi, Koji Sawada, Atsushi Takahashi, Taeang Arai, Tomomi Kogiso, Satoshi Kimoto, Kengo Tomita, Kazuo Notsumata, Michihiro Nonaka, Kazuhito Kawata, Taro Takami, Takashi Kumada, Eiichi Tomita, Takeshi Okanoue, Atsushi Nakajima, Japan Study Group of NAFLD (JSG-NAFLD) |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cirrhosis medicine.medical_treatment Peroxisome Proliferator-Activated Receptors Anti-Inflammatory Agents Apoptosis Review Type 2 diabetes Liver transplantation Gastroenterology Antioxidants Diabetic nephropathy lcsh:Chemistry Liver disease 0302 clinical medicine Non-alcoholic Fatty Liver Disease Diabetic Nephropathies lcsh:QH301-705.5 Spectroscopy Clinical Trials as Topic education.field_of_study General Medicine Computer Science Applications Hepatocellular carcinoma 030211 gastroenterology & hepatology medicine.medical_specialty Population MAP Kinase Kinase Kinase 5 Models Biological Catalysis diabetic hepatopathy Inorganic Chemistry 03 medical and health sciences Internal medicine medicine Humans Hypoglycemic Agents Renal Insufficiency Chronic Physical and Theoretical Chemistry education Molecular Biology Antihypertensive Agents sodium–glucose cotransporter 2 peroxisome proliferator-activated receptor business.industry Probiotics diabetic nephropathy Organic Chemistry nutritional and metabolic diseases sodium-glucose cotransporter 2 medicine.disease digestive system diseases glucagon-like peptide 1 Gastrointestinal Microbiome Prebiotics 030104 developmental biology Diabetes Mellitus Type 2 lcsh:Biology (General) lcsh:QD1-999 Dysbiosis business chronic kidney disease Kidney disease |
| Zdroj: | International Journal of Molecular Sciences, Vol 21, Iss 4939, p 4939 (2020) International Journal of Molecular Sciences |
| ISSN: | 1661-6596 1422-0067 |
| Popis: | Type 2 diabetes (T2D) is associated with diabetic nephropathy as well as nonalcoholic steatohepatitis (NASH), which can be called “diabetic hepatopathy or diabetic liver disease”. NASH, a severe form of nonalcoholic fatty disease (NAFLD), can sometimes progress to cirrhosis, hepatocellular carcinoma and hepatic failure. T2D patients are at higher risk for liver-related mortality compared with the nondiabetic population. NAFLD is closely associated with chronic kidney disease (CKD) or diabetic nephropathy according to cross-sectional and longitudinal studies. Simultaneous kidney liver transplantation (SKLT) is dramatically increasing in the United States, because NASH-related cirrhosis often complicates end-stage renal disease. Growing evidence suggests that NAFLD and CKD share common pathogenetic mechanisms and potential therapeutic targets. Glucagon-like peptide 1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors are expected to ameliorate NASH and diabetic nephropathy/CKD. There are no approved therapies for NASH, but a variety of drug pipelines are now under development. Several agents of them can also ameliorate diabetic nephropathy/CKD, including peroxisome proliferator-activated receptors agonists, apoptosis signaling kinase 1 inhibitor, nuclear factor-erythroid-2-related factor 2 activator, C-C chemokine receptor types 2/5 antagonist and nonsteroidal mineral corticoid receptor antagonist. This review focuses on common drug pipelines in the treatment of diabetic nephropathy and hepatopathy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|